top of page
Product Page: Stores_Product_Widget
Anti-Nucleocapsid (N) Rabbit mAb #VYN7

Anti-Nucleocapsid (N) Rabbit mAb #VYN7


Rabbit Monoclonal Antibody, Recombinant

  • Product Details

    Aliases of the Protein (Antigen)

    Severe acute respiratory syndrome coronavirus 2 nucleocapsid; 2019 novel coronavirus nucleoprotein, SARS-CoV-2 NP, SARS-CoV-2 N protein

    Antigen Background

    UniProt Entry: P0DTC9

    Application Information

    Antigen Molecular Weight: 46 kDa

    Clonality: Rabbit monoclonal antibody

    Clone ID: V700-G5

    Species Reactivity: SARS-CoV-2

    Applications Tested: Western blotting (WB), ELISA, Immunoprecipitation (IP)

    Antigen Subcellular Location

    Virion; Host ER-Golgi intermediate compartment; host Golgi apparatus; host perinuclear region


    Recombinant SARS-CoV-2 nucleocapsid protein


    Rabbit IgG


    Supplied in PBS (pH 7.5) containing  0.01% sodium azide


    Store at – 20°C

    Recommended Dilutions

    Western blotting (WB): 1:2,000

    ELISA: 1:10,000

    Immunoprecipitation (IP): 1:50-1:100

  • Antigen Background

    The single-stranded, plus-sense severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) genome encodes nonstructural replicase polyproteins as well as structural proteins such as spike (S), nucleocapsid (N), membrane (M) and envelop (E) proteins (Zhou et al., 2020). The N protein is abundantly expressed and highly immunogenic during SARS-CoV-2 infection (Cong et al., 2020). The middle or C-terminal region of the N protein has been shown to elicit antibody production during the immune response (Dutta et al., 2020). Although the surface electrostatic potential characteristics of SARS-CoV-2 N are different from other coronavirus N proteins (Kang et al., 2020), the sequences are conserved among these proteins (Dutta et al., 2020). Besides S protein, N protein is also considered a leading target antigen for vaccine development (Chen et al., 2020; Dutta et al., 2020).


    Chen, W.H., Strych, U., Hotez, P.J., and Bottazzi, M.E. (2020). The SARS-CoV-2 Vaccine Pipeline: An Overview. Curr Trop Med Rep, 1-4.

    Cong, Y., Ulasli, M., Schepers, H., Mauthe, M., V'Kovski, P., Kriegenburg, F., Thiel, V., de Haan, C.A.M., and Reggiori, F. (2020). Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. J Virol 94.

    Dutta, N.K., Mazumdar, K., and Gordy, J.T. (2020). The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development. J Virol 94.

    Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., et al. (2020). Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B 10, 1228-1238.

    Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.

  • Product Features

    • Recombinant antibodies with minimum batch-to-batch variations
    • Thoroughly tested using SARS-CoV-2, human nasopharyngeal swabs, and rN
    • No crossreactivity with SARS or MERS




bottom of page